729 related articles for article (PubMed ID: 33163697)
1. The Impact of COVID-19 on Brachytherapy During the Pandemic: A Rutgers-Robert Wood Johnson Barnabas Health Multisite Experience.
Hathout L; Ennis RD; Mattes MD; Wagman RT; Grann A; Jabbour SK; Singh R; Yue NJ; Haffty BG; Vergalasova I
Adv Radiat Oncol; 2021; 6(1):100600. PubMed ID: 33163697
[TBL] [Abstract][Full Text] [Related]
2. Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review.
Parikh S; Zhang Y; Sherwani Z; Kumar R; Ohri N; Jan I; Vergalasova I; Jabbour S; Hathout L
Brachytherapy; 2024; 23(2):141-148. PubMed ID: 38307787
[TBL] [Abstract][Full Text] [Related]
3. A two-center experience: The impact of COVID-19 on two brachytherapy programs in Ontario - virtual care, service suspension and radiation therapy workflow.
Chan K; Timotin E; Chung P; Han K; Milosevic M; Schnarr K; Sur R; Bosche J; Harnett N
J Med Imaging Radiat Sci; 2023 Sep; 54(3):436-445. PubMed ID: 37357051
[TBL] [Abstract][Full Text] [Related]
4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
5. Radical External-Beam Radiotherapy in Combination With Intracavitary Brachytherapy for Localized Carcinoma of the Cervix in Sri Lanka: Is Treatment Delayed Treatment Denied?
Joseph N; Jayalath H; Balawardena J; Skandarajah T; Perera K; Gunasekera D; Weerasinghe S; Hoskin P; Choudhury A
JCO Glob Oncol; 2020 Oct; 6():1574-1581. PubMed ID: 33079608
[TBL] [Abstract][Full Text] [Related]
6. Impact of the Coronavirus Disease of 2019 Pandemic on Radiation Oncology Clinical Decision Making in a High-Prevalence Environment.
Pendyala P; Goglia AG; Mattes MD; Grann A; Huang D; Wagman RT; Yehia ZA; Yoon J; Ennis RD
Adv Radiat Oncol; 2021; 6(3):100680. PubMed ID: 33686375
[TBL] [Abstract][Full Text] [Related]
7. The impact of a positive COVID-19 test on timeliness of radiation in patients receiving brachytherapy.
Roach E; Hutten R; Johnson S; Suneja G; Tward J; Petereit D; Gaffney D
Brachytherapy; 2024; 23(3):360-367. PubMed ID: 38395662
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation.
Williams VM; Kahn JM; Harkenrider MM; Chino J; Chen J; Fang LC; Dunn EF; Fields E; Mayadev JS; Rengan R; Petereit D; Dyer BA
Brachytherapy; 2020; 19(4):401-411. PubMed ID: 32359937
[TBL] [Abstract][Full Text] [Related]
9. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
10. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
11. Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy.
Schlussel Markovic E; Buckstein M; Stone NN; Stock RG
BJU Int; 2018 May; 121(5):774-780. PubMed ID: 29319919
[TBL] [Abstract][Full Text] [Related]
12. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
13. Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma?
Klein J; Ghasem A; Huntley S; Donaldson N; Keisch M; Conway S
Clin Orthop Relat Res; 2018 Mar; 476(3):634-644. PubMed ID: 29443850
[TBL] [Abstract][Full Text] [Related]
14. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).
Crook JM; Zhang P; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Pervez N; Vigneault E; Catton C; Michalski J; Roach M; Beyer D; Jani A; Horwitz E; Donavanik V; Sandler H
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):335-343. PubMed ID: 30312717
[TBL] [Abstract][Full Text] [Related]
15. External beam radiation and brachytherapy boost at different facilities is associated with increased treatment delays in cervical cancer.
Li R; Germino E; Horne ZD; Vargo JA; Chen YJ; Glaser S
Int J Gynecol Cancer; 2020 Oct; 30(10):1505-1512. PubMed ID: 32928924
[TBL] [Abstract][Full Text] [Related]
16. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
[TBL] [Abstract][Full Text] [Related]
17. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
Pasalic D; Barocas DA; Huang LC; Zhao Z; Koyama T; Tang C; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup AM; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
Cancer; 2021 Jun; 127(11):1912-1925. PubMed ID: 33595853
[TBL] [Abstract][Full Text] [Related]
18. Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer.
Sanmamed N; Joseph L; Crook J; Craig T; Warde P; Tomasso AD; Chung P; Berlin A; Bayley A; Saibishkumar EP; Glicksman R; Raman S; Catton C; Helou J
Brachytherapy; 2023; 22(2):188-194. PubMed ID: 36549968
[TBL] [Abstract][Full Text] [Related]
19. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis.
Shen X; Keith SW; Mishra MV; Dicker AP; Showalter TN
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1154-9. PubMed ID: 22270175
[TBL] [Abstract][Full Text] [Related]
20. Comparison of external beam radiotherapy versus permanent seed brachytherapy as monotherapy for intermediate-risk prostate cancer - a single center Canadian experience.
Delouya G; Lambert C; Bahary JP; Beauchemin MC; Barkati M; Ménard C; Taussky D
Can J Urol; 2017 Jun; 24(3):8822-8826. PubMed ID: 28646937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
